You Feel Pain Differently. Your Genes May Explain Why.

The COMT enzyme is responsible for breaking down catecholamines, the chemical messengers that drive pain signaling in your brain and spinal cord. When COMT is working well, it rapidly clears these pain signals, allowing your nervous system to reset. It’s like having an efficient garbage disposal for pain-related chemicals.

The Val158Met variant is the most studied pain-related COMT variant. If you carry the Met variant (sometimes called slow COMT), your enzyme works at reduced efficiency. Roughly 25% of people of European ancestry are homozygous for this slow variant. Slow COMT means pain signals linger longer in your nervous system, creating a lower pain threshold and higher pain amplification. You feel pain more intensely and pain takes longer to resolve.

This translates directly to your experience. A mild headache becomes severe. A minor injury generates intense pain that lasts for weeks. You may notice that stress makes pain worse, because stress increases catecholamine production. You may find that high-intensity exercise or caffeine worsens pain because both elevate these signaling chemicals. Your nervous system has a harder time turning down the volume on pain.

Your body produces its own opioids. Endogenous opioids are molecules your brain manufactures in response to pain, stress, and exercise. They bind to opioid receptors and create natural pain relief and a sense of well-being. OPRM1 encodes the mu-opioid receptor, the primary target for your body’s endogenous opioids. Think of it as the lock, and your body’s natural opioids as the key.

The A118G variant (rs1799971) is the most common pain-relevant OPRM1 variant. The G allele is carried by roughly 10-15% of people of European ancestry, but roughly 40% of people of East Asian ancestry. The G allele creates a receptor that is less sensitive to endogenous opioids; your body’s natural painkillers are less effective at relieving your pain. You have the biological machinery to produce pain-relief molecules, but your receptors don’t respond as well.

This means you experience naturally higher baseline pain, slower pain recovery, and weaker responses to pain medication. You may have noticed that standard doses of pain medication are less effective for you than for others. You may require higher doses or more frequent dosing. You may find that activities that typically produce endorphin surges (running, social connection, laughter) don’t quite give you the pain relief boost that others describe. Your nervous system simply has less efficient pain-relief signaling.

MTHFR catalyzes the methylation cycle, which converts folate into the usable form your cells need. This enzyme is essential for producing neurotransmitters, maintaining DNA integrity, and regulating nitric oxide. Nitric oxide is critical for controlling blood vessel tone in your brain and spinal cord. Poor methylation means poor nitric oxide regulation, which means unstable cerebrovascular function.

The C677T variant is present in roughly 40% of people of European ancestry. The C677T variant reduces MTHFR enzyme activity by 40-70%, impairing your ability to produce methyl groups and regulate nitric oxide production. Your nervous system operates with chronically unstable vascular tone and impaired neurotransmitter synthesis. This affects pain signal processing at the spinal cord level.

For pain, this manifests as a nervous system that is more reactive, more prone to central sensitization, and more vulnerable to pain amplification. You may notice that migraines or headaches accompany pain episodes. You may find that your pain follows a cyclical pattern related to stress or hormonal changes. Your brain’s blood vessels are more reactive, and your nerve cells are operating with suboptimal neurotransmitter levels. Both contribute to lower pain threshold and higher pain intensity.

BDNF is a growth factor that shapes how your nervous system processes pain. In chronic pain, the nervous system undergoes a maladaptive change called central sensitization: the spinal cord and brain amplify pain signals and lower the threshold for perceiving pain. BDNF drives this process. High BDNF activity in pain-processing regions amplifies central sensitization. The Val66Met variant affects BDNF activity and the nervous system’s ability to rewire pain perception.

The Met allele is carried by roughly 30% of the population. The Met allele reduces activity-dependent BDNF secretion, which can actually protect against excessive central sensitization in some contexts but may impair pain recovery mechanisms in others. The Val variant (more common) is associated with higher BDNF activity and may create a nervous system more prone to learning pain patterns and developing chronic pain states.

You likely notice that pain tends to spread or generalize. A localized injury pain evolves into widespread pain. Your nervous system seems to ‘remember’ pain and amplify it with repeated exposure. Stress, poor sleep, and inactivity all worsen pain dramatically. This is central sensitization at work. BDNF variants affect how susceptible your nervous system is to this process and how difficult it is to reverse once established.

GCH1 controls the production of tetrahydrobiopterin (BH4), a critical cofactor for multiple neurotransmitter-synthesizing enzymes. Serotonin, dopamine, and nitric oxide synthesis all require BH4. When BH4 levels are adequate, your nervous system can produce sufficient amounts of these pain-modulating neurotransmitters. When BH4 is depleted, pain signaling amplifies and pain-relief signaling diminishes.

GCH1 variants affecting BH4 production are found in roughly 15-20% of the population. GCH1 variants that reduce BH4 synthesis lower your baseline capacity to produce serotonin, dopamine, and nitric oxide in pain-processing regions, leaving you with a reduced pain-dampening capacity. Your nervous system operates with fewer pain-relief chemicals available.

This creates a pattern where your pain threshold is inherently lower, your pain intensity is higher, and you may notice worsening pain during periods of high stress (which depletes BH4 further through oxidative stress). You may find that activities requiring dopamine and serotonin (motivation, mood, pain resilience) feel harder. Standard pain medications may be less effective because they don’t address the underlying BH4 deficiency driving your pain signaling.

FAAH breaks down anandamide, a naturally occurring endocannabinoid your brain produces in response to pain and stress. Anandamide is sometimes called the ‘bliss molecule’ because it creates pain relief and a sense of calm. When FAAH is working efficiently, it rapidly breaks down anandamide, limiting its duration of action. When FAAH is less active, anandamide lingers longer, extending pain relief.

The C385A variant (rs324420) affects FAAH enzyme activity. The A allele is carried by roughly 20-30% of the population. The A allele reduces FAAH enzyme activity, allowing anandamide to accumulate and persist longer in your nervous system, which is associated with lower baseline pain sensitivity and faster pain recovery. You naturally have more efficient pain-relief signaling through the endocannabinoid system.

If you carry the A allele, you likely notice that you naturally recover from pain faster than others with similar injuries. Stress and pain may feel less overwhelming. You may find that activities that increase endocannabinoid signaling (moderate exercise, social connection, time in nature) provide robust pain relief. Your nervous system has a built-in advantage for pain dampening. Conversely, if you carry the CC genotype, you lack this advantage and may need to actively support endocannabinoid signaling through lifestyle and supplementation.